SUPERIOR PLATFORM FOR STRUCTURE-BASED DRUG DESIGN
OUR DRUG DISCOVERY ENGINE IS DELIVERING AN EXPANDING PIPELINE OF NOVEL GPCR MODULATORS
OUR TEAM IS COMPOSED OF TALENTED BIOPHARMACEUTICAL PROFESSIONALS AND EXPERT SCIENTISTS
Stabilize. Target. Discover. Transform.
Confo Therapeutics’ unparalleled technology stabilizes functional conformations of GPCRs (G protein-coupled receptors) to uncover a wide range of previously inaccessible drug targets.
Confo has attracted an international team of accomplished scientists and business professionals to deploy its innovative drug discovery platform on high value GPCR targets. With these valuable resources in place, Confo’s mission is to build a pipeline of drug candidates with the potential to transform therapeutic outcomes for patients with severe illnesses lacking disease-modifying treatments.
“At Confo, our multi-faceted approach to building value starts from our outstanding technology, our stellar team and a growing proprietary pipeline of novel drug candidates. We further validate our approach through strategic partnerships with industry leaders and a strong consortium of global investors.”
Ghent, Belgium – September 15, 2022 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that it will present highlights from the preclinical profiling of CFTX-1554, Confo’s lead clinical candidate in neuropathic pain, during the International Association for the Study of Pain (IASP) 2022 World Congress on
Ghent, Belgium – June 28, 2022 – Confo Therapeutics announced today that it has been awarded a EUR 1.7 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The award further validates and supports Confo’s leadership in the discovery of novel GPCR (G protein-coupled receptor) drug candidates using its proprietary universal ConfoBody® technology, specifically for the
— Confo’s first drug candidate moves into clinical development — Ghent, Belgium – March 10, 2022 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that the first subjects have been dosed in the company’s Phase 1, first-in-human trial of their clinical candidate CFTX-1554, a novel inhibitor
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.